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All eukaryotic organisms require iron to function. Malfunctions within iron homeostasis
have a range of physiological consequences, and can lead to the development of
pathological conditions that can result in an excess of non-transferrin bound iron
(NTBI). Despite extensive understanding of iron homeostasis, the links between the
“macroscopic” transport of iron across biological barriers (cellular membranes) and the
chemistry of redox changes that drive these processes still needs elucidating. This review
draws conclusions from the current literature, and describes some of the underlying
biophysical and biochemical processes that occur in iron homeostasis. By first taking a
broad view of iron uptake within the gut and subsequent delivery to tissues, in addition to
describing the transferrin and non-transferrin mediated components of these processes,
we provide a base of knowledge from which we further explore NTBI uptake. We provide
concise up-to-date information of the transplasma electron transport systems (tPMETSs)
involved within NTBI uptake, and highlight how these systems are not only involved within
NTBI uptake for detoxification but also may play a role within the reduction of metabolic
stress through regeneration of intracellular NAD(P)H/NAD(P)+ levels. Furthermore, we
illuminate the thermodynamics that governs iron transport, namely the redox potential
cascade and electrochemical behavior of key components of the electron transport
systems that facilitate the movement of electrons across the plasma membrane to
the extracellular compartment. We also take account of kinetic changes that occur to
transport iron into the cell, namely membrane dipole change and their consequent effects
within membrane structure that act to facilitate transport of ions.
Keywords: iron, transplasmamembrane electron transport systems (tPMETS), plasmamembrane oxidoreductase
system, redox, non-transferrin bound iron, electron transfer, transferrin
THE ROLE OF IRON AND ITS UPTAKE INTO MAMMALIAN CELLS
Iron is an essential micronutrient required for normal functioning in mammals (Lieu et al., 2001;
Pantopoulos et al., 2012). Iron’s role as a key element revolves around its abundance in nature and
its multiple oxidation states (being a d-block transition metal), which allow both electron transfer
and the binding to many different ligands. This combination of attributes allows adaptation and
control of iron’s chemical properties to suit the requirements of the cell and results in its essential
role in many processes (Hayashi and Stuchebrukhov, 2010; Kamga et al., 2012).
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This review initially provides a background of the overall iron
transport in the whole organism, to contextualize later in depth
discussion about the specific mechanisms within iron uptake at
the cell level.
Dietary iron can come in two forms: haem bound or non-
haem bound. Haems are a class of porphyrin that contain
ferrous iron. Uptake of haem bound iron may occur across the
duodenal brush border, although the exact mechanism is not fully
elucidated (Sharp and Srai, 2007). Haem carrier protein 1 (HCP1)
has been suggested as a potential uptake transporter for haem
(Shayeghi et al., 2005), but recently it has been proposed that
HCP1 may be a folate transporter unrelated to haem (Qiu et al.,
2006). Non-haem uptake is believed to occur via two methods.
A less studied, less used method is ferritin uptake by enterocytes
(Kalgaonkar and Lönnerdal, 2009). Theil (2004) suggested that
food-derived ferritin could be used as another source of dietary
iron, and Kalgoenkar et al. showed that in Caco-2 intestinal
cells ferritin uptake occurs via receptor mediated endocytosis,
but the receptor which binds ferritin and is then internalized
is yet to be identified. It is important here to note that iron is
stored within ferritin in its ferric form, Fe3+ (Figure 1). They
also state that at high ferritin concentration transport may occur
via micropinocytosis. The second pathway of the transferrin
mediated uptake of non-haem iron is thought not to occur at the
brush border of duodenal entercoytes (Srai et al., 2002), but may
occur elsewhere within the gastrointestinal tract. In this context,
some studies have reported that apotransferrin is not present
within the duodenum of rats (Idzerda et al., 1986) or humans
(Pietrangelo et al., 1992). In addition, and although transferrin
receptors are found in the villous epithelium (Banerjee et al.,
1986) and mucosal cells of duodenum (Huebers et al., 1983), they
are not found at the brush border (Parmley et al., 1985; Banerjee
et al., 1986). These raise the question of how pivotal transferrin’s
role is for iron internalization by duodenal enterocytes and its
subsequent trafficking. It has been suggested that a predominant
method of non-haem iron uptake by duodenal enterocytes at
the brush border is “free” ferrous iron uptake, facilitated by
the Divalent Metal Transport 1 (DMT1) (Canonne-Hergaux
et al., 1999). However before cellular internalization can occur
via these transporters, ferric (Fe3+) iron must be reduced to
ferrous (Fe2+) form, which can be achieved by an enzyme
capable of ferrireductase activity. There is a number of enzymes
that can catalyze this reduction step, but the predominant
candidate within the duodenum is duodenal cytochrome b
(Dcytb) (Latunde-Dada et al., 2002).
Following transport across the apical cytoplasmic membrane
of enterocytes into the cytoplasm by one of the above suggested
mechanisms, ferrous iron can be utilized or sequestered within
the cell, or exported in apical-basolateral direction across the cell.
These former processes commonly occur through biosynthesis
of Fe-S clusters of the electron transport chain (Hayashi and
Stuchebrukhov, 2010) or storage in the form of ferritin (Arosio
et al., 2009), respectively. Storage in mammalian ferritin is
facilitated by ferrous iron oxidation, and subsequent storage, in
addition to detoxification via the consumption of toxic peroxides
involved in the Fenton reaction (Arosio et al., 2009). The 480
kDa, 24-subunit ferritin protein a spherical, but hollow, structure
and can accommodate up to 4,500 ferric iron atoms at any one
time (Finazzi and Arosio, 2014). However it represents a very
small amount of circulating iron and is more abundant within the
cell than in the circulatory system (Arosio et al., 2009). Ebrahimi
et al. have proposed a hypothesis for the ferroxidase capacity
of ferritin that facilitates iron storage as Fe3+ (Honarmand
Ebrahimi et al., 2012). Ferritin can exert ferroxidase activity
through its active center and they suggested that this center
consists of two binding sites that can both bind ferric and
ferrous iron, but with different affinities. There is, in addition, a
gateway to the center present in the form of a third binding site.
Through the binding and catalytic oxidation of two ferrous iron
ions, a ferric iron loaded center, Fe3+-O(H)–Fe3+, is generated
and forms a stable product. When a new ferrous ion binds,
the existing ferric iron is displaced and the new ion undergoes
oxidation to produce ferric iron thus forming the next stable
intermediate. The displaced ferric iron is presumed to form
the core of the ferritin as the method of iron storage, and is
stored as ferrihydrite (Norberg and Rayner, 1987; Chasteen and
Harrison, 1999). A more recent review paper also published by
Ebrahimi et al. (2015) provides more insight into the chemistry
of the catalytic center of ferritin and builds upon their previous
work. Each sub-unit of ferritin that is involved in the process
of ferrous iron oxidation possesses three metal-ion binding sites,
as previously hypothesized. Within eukaryotes, two of these sites
form a di-nuclear metal-ion binding site, named the ferroxidase
center, whilst the third forms an additional metal-ion binding site
close to the ferro-oxidase center.
If not stored or utilized within the enterocyte then ferrous iron
is exported into the circulatory system. Possible mechanisms of
the export across the basolateral cytoplasmic membrane of the
enterocyte include involvement of ferroportin (Dunn et al., 2007)
(the only current putative iron exporter identified to be involved
within iron export throughout the whole body) which works in
concert with the ferroxidase hephaestin (a gut homolog to the
abundant plasma protein ceruloplasmin) to oxidize iron to its
ferric form during the export (Vulpe et al., 1999; Anderson and
Frazer, 2017; Bonaccorsi di Patti et al., 2018). Such exported ferric
ions cross the mucosal interstitial fluid and pass through the
fenestrated capillary endothelium into the bloodstream, whereby
complexation by transferrin occurs (Morgan and Oates, 2002).
This was demonstrated by Morgan et al. (Morgan and Oates,
2002) by measuring iron levels in the lymph and plasma of rats
after administration of Fe3+. They found that only 4% of iron
was present in the lymph, whilst the remainder entered directly
into the blood. They state, “If transferrin had acted as the carrier
of iron from the absorptive cells most of the iron should have
been transported by the lymph because retrieval of extravascular
protein, including transferrin, to the circulation occurs mainly by
this route.” Therefore it is stated that transport of iron into the
intestinal bloodstream occurs in its molecular form.
Transferrin (Tf) is an 80-kDa glycoprotein mainly synthesized
by hepatocytes (Morgan, 1981). It is the major molecule to
complex ferric iron (Fe3+) in the plasma and extracellular
fluids, and is used to transport iron throughout the circulatory
system in its ferric form (Fe3+). Having been exported from
enterocytes and entered the circulation, ferric iron is complexed
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FIGURE 1 | Transport of dietary iron. Ferrous iron can enter the enterocyte cell in the form of haem. The exact method of haem uptake is yet to be elucidated, but
Haem Carrier Protein 1 (HCP1) has been suggested to fill this role. Non-haem ferrous iron can enter the enterocyte cell in the form of ferritin via receptor mediated
endocytosis, although a specific receptor is yet to be identified (Theil, 2004; Kalgaonkar and Lönnerdal, 2009). The main route of iron uptake in the duodenum is of
“free” ferric iron, via a transferrin-independent mechanism. Iron is first reduced into a soluble form via a ferric reductase enzyme at the brush border of duodenal
enterocytes. Transport into the enterocyte is then facilitated by the divalent metal transport 1 (DMT1). Once inside the enterocyte cell ferrous iron can be utilized for
intracellular processes such as haem and Fe-S cluster biosynthesis, or stored in the molecule ferritin. Export primarily occurs, which is facilitated by ferroportin, at this
stage iron is oxidized back to its ferric form by hephaestin. Most ferric iron passes through the fenestrated capillary endothelium of the intestine before being bound by
the glycoprotein transferrin, where it is circulated within the plasma. Here transferrin bound iron can pass via transcytosis (Williams et al., 1984) across the capillary
endothelium and into the interstitial fluid where it is delivered to tissues via transferrin receptor 1 (TfR1) mediated uptake (under normal physiological conditions). In
cases of iron overload a pool of non-transferrin bound iron (NTBI) is formed, in which case iron uptake into most mammalian cells can also occur via NTBI uptake
(Brissot et al., 2012).
by transferrin. Iron bound to transferrin can then be transported
throughout the body via the circulatory system. Transport in the
blood plasma, allows the iron-transferrin complex to transcytose
across the capillary endothelium (Williams et al., 1984) and
deliver transferrin bound iron to interstitial fluid of different
tissues in the body. Transcytosis involves the receptor mediated
endocytosis of the transferrin-iron complex, within vesicles that
subsequently traverse the cell and are exported via exocytosis on
the luminal side (Tuma and Hubbard, 2003).
Transferrin has an extremely high affinity for ferric iron
(Aisen, 1978) at 1024 M−1 and, under normal conditions, only
30% of the body’s transferrin is saturated with ferric iron
(Anderson, 1999). Due to this, it is thought that nearly all ferric
iron in the systemic circulation and interstitial space is in a
transferrin bound form under normal conditions. In a healthy
individual non-transferrin bound iron (NTBI) in the plasma may
still exist, but it does not exceed 1 µmol/L and, is commonly
undetectable (Anderson, 1999). This however will differ in cases
of iron overload (Fleming and Ponka, 2012), where saturation
of transferrin occurs resulting in an increase in free, circulating
ferric plasma iron, not bound to transferrin. This free iron is
referred to as NTBI (Hershko and Peto, 1987). (The term NTBI
generally refers to all iron not bound to transferrin, but is more
commonly used to refer to a low molecular weight pool of iron
within the plasma) (Breuer et al., 2000; Hentze et al., 2004).
Certain diseases, such as hereditary hemochromatosis, can cause
an increase in circulating NTBI (Allen et al., 2008). Conversely,
there are instances where iron deficiency can occur, generally
from blood loss or poor dietary absorption, such as in celiac
disease (Goddard et al., 2011). In cases where the amount of
NTBI increases cells use a non-transferrin mediated method of
iron uptake, similar to that of duodenal uptake at the brush
border (Lane et al., 2015).
Most human tissues express internalizing transferrin receptors
(at least at low levels) (Daniels et al., 2012), such as the transferrin
receptor 1 (TfR1), and so following transport from the systemic
circulation into the interstitial fluid transferrin-mediated uptake
facilitates the internalization of the Tf-Fe3+ complex from the
interstitial fluid into cells.
TWO PATHWAYS FOR IRON UPTAKE:
DIFFERENT ROLES FOR IRON
HOMEOSTASIS
It is clear that there are twomain methods of cellular iron uptake.
The first is the more basic transferrin-independent system, which
is predominantly used when damaging concentrations of NTBI
are present. The second is the transferrin-dependent pathway,
which is used to meet the need for strictly controlled iron
homeostasis. Evidence for this is observed when looking at how
the regulation of the transferrin dependent and independent
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pathways differs by the cell (De Silva et al., 1996). The transferrin
receptors are upregulated when intracellular iron levels are low
(iron deprivation), but there is no upregulation of the non-
transferrin bound pathway (Kaplan et al., 1991; Inman and
Wessling-resnick, 1993). Conversely, we see upregulation of the
non-transferrin pathway when systemic iron overload within the
circulation occurs, in a number of cell types (De Silva et al.,
1996). This leads to the literature’s consensus that the transferrin-
mediated system has developed out of a need for strict internal
control of iron whereas non-transferrin uptake is employed
within crisis, such as iron overload or in cases where less tightly
controlled iron uptake is required, such as for dietary absorption.
Interestingly, besides the gut there is another area of the body
where NTBI uptake systems are routinely employed—the lung.
The lung epithelium is regularly exposed to environmental iron
as a consequence of its function. The lung epithelium therefore
uses NTBI uptake as a mechanism to sequester and detoxify iron
within the cell (Ghio et al., 2006; Ghio, 2009). This lends support
to the consensus that NTBI uptake occurs during the diseased
state as a crisis mechanism during iron overload.
There is evidence to suggest the process of NTBI transport
may have multifaceted functionality, by utilizing the transplasma
electron transport system (tPMETS) that is used to reduce
extracellular iron. One function is that cells may use this pathway
to detoxify iron when iron overload (De Silva et al., 1996)
occurs, through the reduction, uptake and sequestration of ferric
iron. Another is use in times of metabolic stress. Evidence
for the latter was given by studying iron reducing capacity of
respiratory competent vs. incompetent Namalwa cells (Larm
et al., 1995). It was observed that respiratory incompetent
cells reduced ferricyanide at three times the rate of respiratory
competent +Namalwa cells (Larm et al., 1995). This is because
aerobic respiration was absent and due to this, the cell needs
to run the less efficient glycolytic pathway at a greater rate to
provide sufficient energy. Regeneration of NAD+ from NADH is
achieved by the transfer of electrons from NADH to an external
electron acceptor by the tPMETS. This regeneration is reflected
in the greater rate of reduction of extracellular ferricyanide.
These findings are important as they support the hypothesis
that the tPMETSs that facilitate NTBI uptake actually have
multifaceted functionality, either being used to protect the cells
in times of stress or to adsorb iron from the gut. Interestingly,
this NADH/NAD+ equilibrating function appears to also occur
within other cell types when mitochondrial activity is removed,
albeit in relation to tPMETSs involved in cell surface oxygen
consumption. Herst et al. (2004) demonstrated that HL60p0 cells,
which are devoid of mitochondrial DNA, upregulated surface
tPMETSs facilitate the regeneration of NADH/NAD+ levels to
allow for aerobic glycolysis to occur. For this reason, tPMETS
are thought to benefit rapidly propagating cells by yielding a
metabolic advantage through the regeneration of NAD(P)+ at
increased rates. Thus, increased numbers of tPMET centers
supports higher flux through glycolysis, for example in anoxic
conditions.
Where the literature is vague in respect to iron transport is
not the macro-level transport through the body compartments,
or even the methods of uptake, but in the underlying biophysical
and electrochemical mechanisms which underpin the processes
occurring. There is much contention in the literature relating
to the actual mechanisms which are occurring during tPMET,
especially within NTBI uptake. As such, we have sought to the
review contemporary literature regarding the non-transferrin
bound pathway, in addition to summarizing literature on
the electrochemical control of the tPMET that provides the
foundation for “free” iron transport. By combining this with our
highlighting of the multifunctionaility of non-transferrin bound
uptake systems, and specifically the tPMET component of these,
this review succinctly and extensively provides new insights into
how NTBI is both utilized and transported by the body.
The Transferrin-Bound Pathway
Themethod by which iron is transported depends on whether the
iron is bound to transferrin, or not. This section will describe the
transferrin-bound pathway in detail.
Transferrin (Tf)-bound iron cellular uptake (Figure 2) is a
well-understood mechanism of transmembrane iron transport
into cells, which is extensively described within the literature
(Dautry-Varsat et al., 1983; Ohgami et al., 2005; Lane and Lawen,
2008; Lawen and Lane, 2013). Transferrin binds with high
affinity to iron in its ferric form, as discussed. A transferrin-
ferric iron complex (Tf-Fe) can exist in several forms: apo-Tf,
monoferric-Tf or diferric-Tf (holo-Tf) (Lawen and Lane, 2013);
themonomeric form in turn has two possible variants, depending
on iron’s preference for either the N or the C lobe of transferrin
(Makey and Seal, 1976). This binding depends mostly upon the
environmental pH, with the maximal binding occurring at pH
7.4 (Aisen and Listowsky, 1980; Cheng et al., 2004). Normal
conditions usually result in a transferrin saturation of roughly
30% (De Domenico et al., 2008; Pantopoulos et al., 2012). The
Tf-Fe uptake is mediated via the transferrin-receptor-1 (TfR1).
This 95-kDa transmembrane receptor is a homodimer which
preferentially binds holo-Tf (Aisen, 2004). TfR1 is expressed
in most cells, with only a few exceptions, for example mature
erythrocytes (Enns et al., 1982). Upon binding of holo- or
monomeric-Tf to the TfR1, the entire complex is internalized
via receptor-mediated endocytosis, involving clathrin-coated pits
(Qian et al., 2002). Within 2–6min (Dautry-Varsat et al., 1983)
the internalized endosome experiences a decrease of pH to 5.3–
5.6 (Dautry-Varsat et al., 1983; Klausner et al., 1983). This change
in pH is driven by a vacuolar-type H+-ATPase (V-ATPase), a
transmembrane protein of the endosome (Presley et al., 1997).
The resulting acidic environment causes ferric iron to dissociate
from Tf (Dautry-Varsat et al., 1983; Paterson et al., 1984), whilst
the now apo-Tf remains bound to the TfR1. Recent work by
Eckenroth et al. (2011) have shown the binding of Tf to its
receptor induces structural changes within the TfR ectodomain
that prime Tf for release, this occurs through alteration of the
Tf-TfR1 interaction upon a change to acidic pH.
Following release from the transferrin molecule, the
dissociated ferric iron is reduced via ferri-reductases. It is
important to note this process occurs on the endosomal
membrane, and there are both similarities and differences
in relation to the non-transferrin bound pathway. In this
transferrin-bound pathway, the ferri-reductases used to achieve
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FIGURE 2 | The transferrin bound cycle of iron uptake. Ferric iron binds to
transferrin to form holo-transferrin (Tf). This di-ferric complex then binds to the
transferrin receptor 1 (TfR1). Upon binding to the TfR1, the whole complex is
internalized via receptor-mediated endocytosis. An ATP driven H+ pump
drives a pH reduction within the endosome, which causes dissociation of ferric
iron from transferrin. The unbound ferric iron is reduced via a transmembrane
ferri-reductase to form ferrous iron. The ferrous iron is then transported into the
cytoplasm by the DMT1 transporter. The receptor and transferrin protein are
then recycled to the surface, ready for the cycle to repeat (not shown).
Adapted from Lawen and Lane (2013).
this are the 6-transmembrane epithelial antigen of the prostate-3,
steap3 (Ohgami et al., 2005), and/or members of the cytochrome
b561 family (Lane and Lawen, 2009). Once ferrous iron has been
formed, transport out of the endosome is facilitated via DMT1,
as discussed previously (Andrews, 1999; Garrick et al., 2003).
It has also been suggested that ZRT/IRT-like protein (Huebers
et al., 1983) (ZIP14) can facilitate ferrous iron transport out of
the endosome (Tripathi et al., 2015). Ferric iron reduction occurs
because the DMT1 transporter only transports iron in its ferrous
form, in addition to iron being required in its soluble, reduced
form. The DMT1 and cytochrome b561 family are also used in the
non-transferrin pathway, but steap3 is not, and is only used at
the endosomal membrane of the transferrin-bound path. Finally
the apo-Tf/TfR1 complex is recycled back to the cell membrane
to be re-used (Morgan, 1996). It is here, at physiological pH,
that apo-Tf dissociates from the receptor (Bomford et al., 1985).
In this way the transmembrane ferri-reductase-DMT1 system
present in the endosomal membrane is used to facilitate ferric
iron movement into the intracellular compartment.
The Non-Transferrin Bound Pathway
The second method of non-haem iron uptake into mammalian
cells is that of a non-transferrin bound pathway. This pathway
uses transplasma membrane electron transport (tPMET) at
the cell plasma membrane to reduce iron, as opposed to the
endosomal membrane tMET that occurs within the transferrin-
bound pathway. The presence of multiple iron uptake systems,
which the cell can exploit, are predicted to have arisen from
how evolutionary biology has steered cellular iron homeostasis.
Most prokaryotes and single-celled eukaryotes, likemulti-cellular
organisms, require iron. Due to the high amounts of iron that
is in inaccessible forms these organisms have had to develop
various methods to acquire the environmental iron they may
encounter (Wandersman and Delepelaire, 2004). Siderophores
(Neilands, 1995), which are low molecular weight ferric iron
chelators, are one way in which bacteria seek to harvest iron
from their surroundings. Other mechanisms include acquisition
of iron from host systems (Guerinot, 1994), or the use of ferri-
reductases to reduce iron prior to transport across the plasma
membrane (Guerinot, 1994; Shatwell et al., 1996). Much like the
latter method for acquisition within single-celled organisms, it
is thought that most eukaryotes possess a system of ferric iron
reduction and subsequent transport that can be used to obtain
iron from their surroundings in the event of iron overload and
the risk of iron toxicity, except for the absorptive intestinal cells
that acquire iron for dietary needs, and for iron detoxification
at the lung-air interface. The following section outlines the
tPMETSs involved in the non-transferrin bound uptake pathway.
ENZYME-MEDIATED ELECTRON
TRANSFER: A GENERAL MODEL
Biological membranes exist to enable cells and their organelles
to control their environment by acting as selectively permeable
barriers. Redox centers exist in membranes that are involved
in bioenergetics and are located both in cytosolic structures
such as in the endoplasmic reticulum, and in the plasma
membrane. These redox centers function to transport electrons
across membranes and are known to be involved in iron
reduction. The centers have been termed as either (trans)plasma
membrane electron transport systems (tPMETS or PMETS) or
plasma membrane oxido-reductase (PMOR) centers (Berridge
and Tan, 1998, 2000; Baker and Lawen, 2000). A general model
for tPMETSs that involves naturally occurring electrochemical
mediators has been proposed (Figures 3A,B) (Morré and Morré,
2004). This general model consists of a redox enzyme system
that spans the plasma membrane and is comprised of three
components. One component faces the cytoplasm, another
element acts within the hydrophobic lipid bilayer and the
third interfaces with the cell’s external environment. The ferri-
reductase used as a tPMETS, as well as the redox couple
employed, can differ; this will depend on where the system
is being employed. Interestingly, evidence has already been
reported that there is more than one membrane redox system
capable of reducing ferric iron (Rawson et al., 2014) in
eukaryotes.
Ferri-reductase systems have been extensively covered in
the literature. There are several of these redox systems that
have been proposed, and it has been suggested they are of
“two types” (Lane and Lawen, 2009). One is dependent on
enzyme-mediated iron reduction while the other relies on a
natural redox mediator, such as ascorbate, and is independent of
enzyme-iron interactions which will be discussed later in the text
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FIGURE 3 | (A). Generalized, traditional model of non-transferrin bound iron uptake. A reversible redox couple provides electrons to the ferri-reductase, through its
oxidation from a reduced to an oxidized form. Facilitated by the reductase, these electrons are used to reduce two molecules of ferric ion to form ferrous ion in the
extracellular compartment. This ferrous ion is co-transported across the cell membrane with H+ ions, into the intracellular space; this is facilitated by the DMT1
transporter. The DMT1 transporter also acts as a uniporter, and “leaks” H+ ions to the intracellular compartment from the extracellular compartment. (B) Ubiquinone
shuttle of NADH-ferri-reductases. It has been shown that coenzyme Q can facilitate electron transport through the membrane of cells for the NADH-ferri-reductases
(Oakhill et al., 2008). This schematic proposes a method of how this can occur, based upon the mechanisms of coenzyme Q electron shuttling within complex I and II
of the electron transport chain. (C) Schematic of the favored electron transfer pathway in a general transplasma membrane electron transport system according to the
(in some cases approximated) standard redox potential at pH 7.
(Figure 4). The intracellular facing part of the general enzymatic
based tPMETS (Figures 3A,B) functions by undergoing redox
reactions, utilizing intracellular redox mediators. These are
known to occur with the nicotinamide adenine dinucleotide
phosphate couple (NAD(P)H/NAD(P)+) (Baker and Lawen,
2000) (Figure 4, Equation 4), ascorbate/dehydroascorbate
(Asc/DHA) couple (Figure 4, Equations 1, 2) (Van Duijn et al.,
1998), and suspected to occur with the glutathione/glutathione
disulphide couple (GSH/GSSG) (Figure 4, Equation 5). The
lipophilic component of the tPMETS (Figure 3B), that mediates
electron transfer to the outward facing component, is proposed
to be Coenzyme Q. Coenzyme Q is synthesized in mammals by
all cells (Navas et al., 2007), and is present within all membranes
of the cell (Kalén et al., 1987; Sun et al., 1992). Coenzyme
Q’s role has been well-documented in transporting NADH
derived electrons through the membrane, from one complex
of the Electron Transport Chain to the next (Lodish et al.,
2007). In addition, it has been demonstrated that for NADH
oxido-reductases, the hydrophobic coenzyme Q, also known as
ubiquinone, is responsible for the shuttling of electrons to the
ferri-reductase (Sun et al., 1992).
In the case of the NADH dependent ferri-reductase, which is
an enzyme based tPMET (Figure 3A), oxidation of intracellular
NADH to NAD+ causes the production of free electrons and
a H+ ion. The electrons and the H+ ion, and an additional
intracellular H+, then cause the reduction of coenzyme Q to
form reduced coenzyme Q, or ubiquinol (with the addition
of 2 H+). The subsequent reduced coenzyme Q molecule
shuttles the electrons through the membrane to be used to
reduce extracellular ferric iron. It is important to note that the
use of reduced coenzyme Q for shuttling is localized in the
membrane.
Enzyme Based Ferrireduction: The
Enzymes That Fit the Classic Model
A number of different ferri-reductases have been identified,
which fit the classical model discussed above (enzyme-mediated
electron transfer), however they differ both in structure and
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in the site where they are expressed. tPMETSs have been
shown to be multicomponent (Lesuisse et al., 1996). The
proteins of each component have been segregated from cellular
membranes and their sequence has been elucidated. It has been
demonstrated that the sequences of the tPMET components
are closely related to cytochrome b5, cytochrome c, protein
disulphides and various ferrichelates (Morré and Morré, 2004).
The redox half-wave potentials of, for example, cytochrome
b5 and cytochrome c, that display similar sequence homology
to isolated tPMETS components, are known to span a wide
range from approximately between −0.035 (Aono et al., 2010)
(for the reductase) to 0.25V (Eddowes et al., 1980) (for
the oxidase) vs. Normal Hydrogen Electrode. Importantly,
from a thermodynamic view, the potential of the reductase
is significantly more positive than that of the NADH/NAD+
(−0.324V) or NADPH/NADP+ (−0.339V) couples, while the
potential of the oxidase is more negative than that of the
Fe(II)/(III) couple which results in electron transfer via a Q-
reductase. As shown in Figure 3C, this allows for electron flow
from the intracellular to the extracellular compartment. It is
thought this is to increase the solubility of the iron and thereby
facilitating intracellular iron transport (more detail is given in
later sections). However, much work is still to be performed to
elucidate the exact structure and function of tPMET centers, and
to provide a more complete understanding of their roles in the
cell.
It is currently hypothesized that in enterocytes duodenal
cytochrome-b ferri-reductase (Dcytb) reduces ferric ion at the
apical membrane in preparation for iron uptake. However,
some studies have shown that the level of iron uptake does
not significantly reduce in mice with Dcytb-knockout (Gunshin
et al., 2005). Dcytb is highly expressed at the duodenal
enterocyte brush border and is a member of the cytochrome
b561 family (Oakhill et al., 2008). The cytochrome b561 family
displays strong sequence homology between its members, and
constitutes a group of multi-pass transmembrane enzymes
found only in eukaryotes (Lu et al., 2014). Dcytb is a 286
amino acid, six transmembrane domain protein (Wyman et al.,
2008), that acts as an oxidoreductase that transfers electrons
from cytosolic ascorbate to extracellular electron receptors
(Vlachodimitropoulou et al., 2010). It has been shown to be
expressed in a wide variety of cell types including human
erythrocytes (Su et al., 2006), lung epithelium (Turi et al.,
2006), K562 cells (Kovar et al., 2006), astrocytes (Loke et al.,
FIGURE 4 | Current ascorbate cycling model for NTBI reduction and uptake. Ascorbate provides the necessary reducing equivalents to reduce ferric iron to ferrous
iron, by becoming oxidized to DHA. Fe2+ is then transported, putatively by DMT1, across the membrane. DHA is now cycled back to the intracellular phase via
glucose transporters such as GLUT1. Internal regeneration of DHA to ascorbate occurs via direct two-electron reduction using glutathione/glutathione disulfide couple
(GSH/GSSG). Reduction also occurs enzymatically using NADPH and GSH dependent enzymes. The regenerated ascorbate crosses the membrane via anion
channels and the process repeats.
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2013), Caco-2 (Balusikova et al., 2009), and HEP-G2 cells
(Anderson, 1999). Four of its transmembrane helices contain
a single histidine haem-binding residue, which is organized to
construct two iron coordination complexes. Development of this
his-binding model resulted in identification of two potential
substrate-binding sequences, which are conserved between the
cytochrome b561 family (Okuyama et al., 1998). The first
sequence, ALLVYRV, between residues 68 and 74, is located at the
end of alpha-helix II. It forms an ascorbate recognition/binding
region with Lys83. The second, SLHSW is between residues 119
and 123 and is thought to adopt a location between helices II and
III. This sequence is proposed to form another ascorbate or DHA-
binding site (Okuyama et al., 1998). This sequence binding data
supports the enzyme-mediated explanation where ferric iron is
reduced by intracellular electron donors such as ascorbate. The
most current characterization of the Dcytb protein by Ganasen
et al. (2018) suggests an electron transfer pathway whereby
an electron from intracellular ascorbate passes to extracellular
iron or the ascorbyl free radical via two histidine-coordinated
hemes.
Another ferri-reductase, previously mentioned as part of the
transferrin-dependent pathway, is Steap3. This STEAP family
protein is partially homologous to the oxidoreductases found
in bacteria and archaea, and to the FRE metalloreductase in
Saccharomyces cerevisiae (Ohgami et al., 2005, 2006). It plays
a key role in the reduction of ferric iron within the endosome
of erythroid cells, following the internalization of the Tf-
ferric iron complex via endocytosis. It is this reduction that
occurs prior to transport of the reduced ferrous iron into the
intracellular compartment. Steap3 is comprised of a C-terminal
transmembrane domain, which is thought to coordinate a single
intramembrane haem. An N-terminal cytosolic oxidoreductase
domain is also present which uses cytosolic NADPH as a cofactor
and is predicted to also use flavin as cofactor to reduce ferric iron
because of the presence of a putative flavin binding site (Ohgami
et al., 2005; Sendamarai et al., 2008).
The electron transfer process is proposed to consist of
sequential electron transfer from cytosolic NADPH to the flavin
and intramembrane haem, and finally to the ferric iron within
the endosome (Sendamarai et al., 2008). The mechanism of
electron transport, mediated by these ferri-reductases, is both
relevant and important to further understanding the intricacies
of these systems. It has been suggested that the electron
transport mechanism that Steap3 exhibits is a gated system,
where electron flow into the endosome only occurs in response
to a need for ferric iron reduction. An obvious possibility for
how this selective mechanism works is a structural change
in response to ferric iron interaction, thus allowing electron
flow into the endosome. The structural clarification of the
oxidoreductase domain by Sendamarai et al. points to other
possibilities (Sendamarai et al., 2008). Due to the proximity of
the active site to the dimer interface of Steap3, the oligomeric
state of the enzyme may strongly affect the catalytic ability of
the enzyme and regulate its oxidoreductase activity (Sendamarai
et al., 2008). Another possibility is that Steap3 is mediated
by other members of the transferrin-bound pathways, such as
DMT1.
Enzymes of the Non-Classical Model
Although tPMET centers described above have been postulated,
other centers with variations on this theme have been
proposed to exist, such as purely cell-surface based complexes
(Berridge and Tan, 1998). Lawen et al. (2005) have shown that
the mitochondrial voltage-dependent anion-selective channel
1(VDAC1) that also exists in the cell membrane, acts as a
ferricyanide reductase at that site (De Pinto et al., 2003).
Voltage-dependent anion-selective channel 1 (VDAC1) is a
30–35 kDa protein, which is localized within the outer
mitochondrial membrane. The function of VDAC1 within the
plasmamembrane was unknown, until Baker et al. published data
showing that VDAC1 was in fact a NADH-ferricyanide reductase
(Baker et al., 2004). They used immunoprecipitation directed
against VDAC1 to show that preparations purified from plasma
membrane and mitochondrial fractions that exhibited NADH
ferricyanide reductase activity were in fact VDAC1. An additional
publication by Baker et al. succinctly reviews the data for NADH-
oxidoreductases, and may prove useful for readers of this review
(Baker and Lawen, 2000). It is likely that more membrane sites
capable of iron reduction will be identified (Rawson et al., 2014).
The Ascorbate Shuttle Model
Another non-classical iron reducing transporter system
that has been described involves the membrane electron
mediator ascorbate. Ascorbate, more commonly known as
vitamin C, is maintained in the cell at an outward facing
concentration gradient (high intracellular concentration). This
gradient is generated and maintained mostly via the sodium-
dependent import of ascorbate into cells by sodium-ascorbate
co-transporters (SVCTs 1 and 2) (Savini et al., 2008). In addition
to the SVCTs, the mammalian facilitative glucose transporters,
GLUT1, GLUT3, and GLUT4, can transport dehydroascorbate
(DHA) into the cell, where it is then rapidly reduced to ascorbate,
thus maintaining both the DHA and ascorbate gradients.
Ascorbate is also released from the cell via anion channel
transport, but the physiological functions of this are not entirely
clear.
One of the first suggestions of a mechanism that uses
intracellular ascorbate accumulation as opposed to an NADH-
dependent ferrireductase was from Van Duijn et al. (1998). In
this paper they identified that loading HL-60 myeloid leukemic
cells with ascorbate stimulated ferricyanide reductase activity in
a mechanism distinct from the NADH-ferricyanide reductase
pathway. However, they did not elucidate whether this was due
to a shuttling mechanism or, as we now know, the potential
utilization of intracellular ascorbate by enzymes such as Dcytb.
Lane et al. previously suggested that DHA can undergo
reduction by an electron shuttle mechanism to form ascorbate
(Figure 4, Equation 1), which crosses the plasma membrane via
transmembrane anion channels and through its own oxidation
(Figure 4, Equation 2) acts directly to reduce extracellular ferric
iron (Lane and Lawen, 2008, 2009) (Figure 4, Equation 3).
Indeed, this mechanism has recently been shown to be active in
plants (Grillet et al., 2014). This process is thermodynamically
favorable as ascorbate-DHA couple has a standard redox
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potential of +0.058V (pH 7) vs. the 0.372V (pH 7) of a typical
iron chelate, such as ironIII citrate (Figure 3C).
Intracellular redox couples (R/O) provide the electrons that
are donated to DHA in Figure 4, Equation 1, in much the same
way as previously described for the generic system presented in
Figure 3. These redox couples either donate electrons directly
or enzymatically, reducing DHA back to ascorbate (Linster
and Van Schaftingen, 2007). Reduction of dehydroascorbate to
ascorbate is facilitated within the cytosol by direct non-enzymatic
reduction via glutathione (Winkler, 1992); by the NADPH-
dependent enzymes thioredoxin reductase (May et al., 1997) or
3-alpha-Hydroxysteroid dehydrogenase (Del Bello et al., 1994);
or through the gluthathione-dependent enzymes glutaredoxin
(Wells et al., 1990), protein sulfide disomerase (Wells et al., 1990),
and omega class glutathione transferase (Maellaro et al., 1997).
As outlined above, the release of ascorbate from the cell is
facilitated via anion channels. Although the specific channels
have not been identified for this particular tPMETS, it has
been shown that physiologically this can occur using a variety
of mechanisms. These include volume-sensitive and Ca2+-
dependent anion channels (VSOAC), gap-junction hemichannels
and exocytosis of secretory vesicles (Corti et al., 2010). Once
released, direct interaction of ascorbate with ferric iron indicates
that it mimics a ferri-reductase. This has further implications as
it suggests this ascorbate-based cycling mechanism, in addition
to an enzyme mediated transmembrane electron transfer
mechanism (Figure 3), can be responsible for the reduction of
ferric iron.
Lane et al. (Lane and Lawen, 2009) has previously highlighted
the regulated release of intracellular ascorbate into the
extracellular compartment, and discussed how this eﬄux
constitutes an additional tPMETS. Their research indicated that
this non-classical ascorbate export, which is achieved through
the use of plasma membrane conduits and/or exocytosis, occurs
as an alternative method of ascorbate-dependent tPMET.
This is in contrast to the classical enzymatic electron transfer
system, which uses the redox centers of plasma membrane
ascorbate oxidoreductases such as Dcytb. Interestingly the
paper suggests that the shuttling transport mechanism is not
likely to be a general mechanism for ascorbate-stimulated
iron reduction and that observations demonstrate that in
a conditioned medium of ascorbate-supplemented cells a
stimulation of ferricyanide reduction could not be induced
despite a stimulation of ferric citrate reduction being possible
through external ascorbate (May, 1999; Lane and Lawen, 2009,
2014). This is an important observation, which leads to the
conclusion that there are two mechanisms used differentially
for different iron compounds within the cited work. The
physiologically relevant iron compound ferric citrate requires
ascorbate to be eﬄuxed from the cell for a stimulation of
iron reduction to occur. In contrast, ascorbate can stimulate
the reduction of non-physiological compounds (such as
ferricyanide) by both ascorbate eﬄux mechanisms across the
plasma membrane and “classical” enzymatic-based tPMET.
In the same ascorbate-focused review of tPMET, Lane et al.
(Lane and Lawen, 2009) also look at the possibility of the
ascorbate free radical (AFR) in the reduction of extracellular
iron, and there is evidence to suggest Dcytb can act as
such.
Ascorbate has additionally been shown to have a function in
the uptake of iron into astrocytes. Lane et al. demonstrated that
when astrocytes were ascorbate-deficient, a yet unknown ferric
iron uptake pathway predominates, but in ascorbate-replete
systems both ferric and ferrous pathways are present. They state
that in the ascorbate-replete system ferric iron is directly reduced
via ascorbate, before transport into the cell via DMT1 (Lane et al.,
2010). This further builds on the published work of Lane et al. on
the role of ascorbate in ferrireduction and iron homeostasis.
Other more recent developments in this area include the work
of Eccardt et al. (2017), who identify an ascorbate shuttling
mechanism in skeletal muscle cells. It is clear that ascorbate is
an important molecule for NTBI reduction and uptake within
mammalian cells, but there are still questions to be answered on
the exact mechanisms occurring.
BIOCHEMICAL CONTROL OF ELECTRON
TRANSFER VIA TPMETS
Whether it is by an enzyme dependent or independent pathway,
the tPMETSs’ function relies on the interaction of natural
redox mediators. These are defined as molecules that are
able to transfer electrons efficiently to a biocatalyst (Thévenot
et al., 2001) and are intrinsic to the cells’ ability to reduce
extracellular iron. Consequently, the redox characteristics of the
tPMETS must be considered to understand electron transport
limitations controlling iron reduction and therefore transport
via the ferri-reductase-DMT1 linked tPMET. Representing the
external pool of iron to be transported via non-transferrin
bound pathways that involve tPMETSs as “FeIIIOx,” and the
tPMETS as a whole as “Cellred” a simplified expression can
be written for the overall reduction of ferric iron to ferrous
iron (Equation 6). Although it is commonly assumed that
the standard redox potentials of components of an electron
transport chain must increase going from the initial electron
donor to the final electron acceptor, the situation can be
described by the Nernst equation for the system. For the redox
reaction shown in Equation (6), the Nernst equation is given by
Equation (7).
FeIIIox+Cellred ⇌ Fe
II
red+Cellox (6)
where Ecell is the cell potential, E
θ
cell
is the standard potential for
the cell (Eθ
cell
= Eθ (FeII
red
/FeIIIOx/Fe) – E
0(Cellred/Cellox)), R =
the gas constant (8.314 J K−1), T= temperature (assumed to be
298K), F is Faraday’s constant (96,487Cmol−1) and n= number
of electrons transferred (assumed to be one).
Ecell = E
θ
cell −
RT
nF
ln
[(aCellox)][Fe
II
red
]
[FeIIIox][(aCellred)]
(7)
At equilibrium, Eθ cell = 0, and hence the Nernst equation
allows the position of the equilibrium for the reaction shown
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in Equation (6) to be determined. By considering the form of
the Nernst equation, the following general comments can be
made (based on thermodynamics only) pertinent to electron
transfer from the cells to the external oxidized iron pool. When
Eθ
cell
> 0, electron transfer as represented by the forward
direction in Equation (6) will not necessarily be complete, and
conversely, even when Eθ
cell
< 0 electron transfer may proceed
to some extent in the forward direction. In other words, the
extent of electron transfer from Cellred (the tPMET) to Fe
III
ox (the
extracellular iron) depends on the concentration ratio of FeIIIox
and FeII
red
to cellular redox sites and also whether the reaction
products are rapidly being re-converted to their initial forms
to partake in the reaction again. In mammalian cells, the non-
transferrin bound pathway has been reported to be more active,
and operate more in situations where environmental iron is
increased. It was stated that to deal with increases in extracellular
iron, this upregulation of non-transferrin transport was required
(Kaplan et al., 1991). Interestingly, no increased protein content
was observed, and so an assertion was made that the reason for
this increased transport via the non-transferrin pathways was as
a result of a post translational modification to an already existing
transporter. This means that the ratio of FeIIIox : Cellsred would
increase in situations where the extracellular NTBI levels rise
and the equilibrium shown in Equation (6) would be pushed
in the forward direction resulting in more iron being reduced
when under thermodynamic control. Despite this observation
others have noted that in iron deficient diets all cells or tissues
upregulate DMT1 (Gunshin et al., 1997). In addition to this, the
increased transport of FeIIIOx via non-transferrin bound pathway
may also occur due to local electronic effects, which increase
transport through the DMT-1, which is discussed in the following
section.
DMT1 ION TRANSPORT
At this point it is important to give more detail on the DMT1
transporter, namely the divalent metal transporting protein that
forms the link with the tPMETSs that have been discussed,
both transferrin and non-transferrin related. There is little
known about the transporter DMT1, especially how DMT1
specifically targets divalent metals and the exact mechanisms
by which transport occurs. DMT1 is also known as natural
resistance-associated macrophage protein 2 (or Nramp2), and
is encoded by the SLC11A2 gene. Mutation in the gene has
been shown to play a role in such diseases as microcytic
anemia and disease overload characteristics (Mims et al., 2005;
Beaumont et al., 2006; Iolascon et al., 2006), indicating its
role within iron transport. Despite being important for iron
transport, DMT1 can also transport a host of other transition-
metal ions, including copper, manganese, cobalt, cadmium,
nickel, vanadium, and lead (Ehrnstorfer et al., 2014). DMT1
is ubiquitously expressed in all cell types, with its varying
isoforms being expressed in different tissues (Soe-Lin et al.,
2010). The different isoforms arise from splicing variants of the
gene product, and variation in the structure of their 5′ and 3′
ends.
It has been demonstrated by Mackenzie et al. that all
four isoforms function as metal-ion transporters of equivalent
efficacy, with all managing to mediate ferrous iron uptake via a
H+-coupled mechanism (Mackenzie et al., 2007). The authors
indicated that its transport was controlled to an extent by the
H+ inducing an electrochemical potential gradient. This was
supported by Gunshin et al. who were one of the first to report
on an insight into the mechanism by which transport is driven
through DMT1 across the membrane (Gunshin et al., 1997).
They stated that the process by which DMT1 mediates active
transport of ferrous iron is voltage-dependent, and is coupled to
the movement of H+ ions down their electrochemical gradient,
into the cell. This was first proposed by Gunshin et al. (1997),
but has also been confirmed by Mackenzie et al. in multiple
publications (Mackenzie and Hediger, 2004; Mackenzie et al.,
2006, 2007). They demonstrated that iron transport at low
pH led to intracellular acidification, and with the pre-steady
state currents observed during their electrochemical analysis,
concluded that iron transport was pH dependent, thus indicating
that H+ acts on theDMT1 to facilitate iron transport. In addition,
they have also highlighted the importance of His-272 in this
coupling process and suggested that protonation of this residue
may be a requirement for H+-coupling (Mackenzie et al., 2006).
The same conclusions have been drawn for the yeast homolog of
DMT1, SMF1. Chen et al. demonstrated that when expressed in
Xenopus oocytes, the SMF1 transporter exhibits proton-coupled
metal cation transport but in addition, the transporter also uses
proton-uncoupled transport of metal ions, not requiring H+ ions
(Chen et al., 1999). Interestingly they also confirm the existence
of the uncoupled “leak” pathway first suggested by Gunshin et al.
Gunshin et al. also speculate that concomitantly with this path,
the DMT1 acts as a H+ uniporter that “leaks” H+ ions into the
intracellular compartment, which was confirmed by Mackenzie
et al. (2006).
In addition, Mackenzie et al. also provided evidence that Fe2+
transport could also occur in an unlinkedmanner independent of
protons, driven by the effect of membrane potential differences,
albeit at a slower rate compared to coupled transport (Mackenzie
et al., 2007). This suggests that the external pH and iron
concentration is used as a means to facilitate and regulate the
degree of non-transferrin dependent transport of iron.
These data combined raise some interesting questions
regarding the biochemical mechanisms that control the rate of
iron transport via tPMET-DMT1 iron transport systems, which
are yet to be solved. One of the most important is what aspect
of ion transport through DMT1 is voltage-dependent. It was
demonstrated that the co-transport of H+, which facilitates
increased iron transport, was as a result of the protonation of
a histidine within DMT1. It was suggested that this made the
transport more thermodynamically favorable. However, Mares
et al. (2014) have recently demonstrated that it not necessarily
the binding of ions to a membrane extracellular transport site
that is voltage dependent as classically thought (O’Shea, 2014),
but is the occlusion of ions within the protein which is voltage
dependent (Figure 5); occlusion being defined as the entrapment
of an ion in a protein matrix. Binding ions such as H+ within
DMT1, or an increase in charge interactions induced by changes
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FIGURE 5 | Membrane occlusion and intramembrane dipole potentials. (A) In the non-occluded state, the membrane is in a state of thinner (compared to B)
hydrophobic thickness leading to a structural changes in the membrane protein. This in turn produces a low lipid packing density and thus low membrane potential.
Panel (B) illustrates the opposite, where the occluded state leads to high packing density and thus high membrane potential. The increased hydrophobic thickness
resulting from the occluded state causes these changes. Diagram adapted from Mares et al. (2014).
in pH may affect the intramembrane dipole potentials. This in
turn favors increased transport via changes in protein structure.
These changes may be induced by voltage-geometric changes
that occur within the membrane, which accompany transporter
protein structural changes during occlusion and de-occlusion of
the ion. Therefore, when considering the controllingmechanisms
that determine transport through DMT1, it is important that this
newly identified phenomenon is taken into consideration and
further requires major experimental attention to determine the
role that movement of charges across and within the membrane
play in controlling iron transport via DMT-1.
OTHER NOTABLE EXAMPLES OF
MEMBRANE BOUND IRON REDUCING
SYSTEMS
Ferrireduction does not necessarily require enzyme-mediation,
or shuttling of reversible redox pairs. Prion diseases are
neurodegenerative conditions in which the prion protein (PrPC)
undergoes conformational changes to an aggregated, damaging
form named PrP-scrapie (PrPSC). Haldar et al. have shown that
the PrPC, using kidney proximal tubule (PT) cells, increases the
uptake of NTBI and Tf-bound iron into the PT cells in vivo, and
NTBI in vitro (Haldar et al., 2015). This is achieved by PrPC
acting as a ferri-reductase, which reduces iron thus making it
more soluble to enable it to possibly be transported through
transporters, and Tripathi et al. have since demonstrated that
PrPC acts as a ferri-reductase partner for both ZIP14 and DMT1
(Tripathi et al., 2015). Anion exchange has also been implicated
in iron uptake in human bronchial epithelium cells by Ghio
et al. (2003), where they showed the anion exchange protein 2
(AE2) facilitated the outward flux of superoxide for inward flux
of bicarbonate, subsequently leading to superoxide mediated iron
reduction.
In addition to the aforementioned routes of iron transport,
there is another way iron can transverse the plasma membrane.
This transport does not occur inwards, but outwards, via the
protein ferroportin. Ferroportin or “solute carrier family 40
member 1” (SLC40A1) is the sole cellular eﬄux channel for
iron, and is regulated by the hormone hepcidin, as discussed
previously. The binding of hepcidin to ferriportin results in
the internalization of the complex and subsequent degradation;
meaning it is used when plasma iron levels are too high, or
more iron is required within the cell (Donovan et al., 2005;
Forman, 2005). Regulation of DMT1 and ferriportin, enables
the flow of iron into and out of the cell to be carefully
controlled.
Another review which covers the broader uses of tPMETs in
general (not just the traditional models, and not just specifically
relating to iron reduction) by Ly et al. may also be of use (Ly and
Lawen, 2003). Another exceptional review regarding the broader
context of mammalian tPMET and its implications for health and
disease can be found by Del Principe et al. (2011).
In this review we have focused only upon the uptake of
iron into mammalian cells, in substantial detail. A recent review
published in Nature Reviews Drug Discovery by Crielaard et al.
(2017) looks more broadly at iron homeostasis, with particular
focus on targeting iron for drug discovery and delivery. It may be
of interest to anyone reading this review who is seeking a broader
overview of the topic.
CONCLUSIONS
This review focuses upon the use of, and different mechanisms, of
NTBI uptake, and more specifically the transplasma membrane
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transport (tPMET) that underpin the functionality of these
systems. This review has sought to draw together previously
unlinked data, namely how redox potential electrochemistry
of the components of electron transfer lead to governance of
biochemical control of tPMETSs, and how this interplays with
NTBI transport on a macroscopic scale. We further seek to raise
questions about how intramembrane dipole changes can lead
to a membrane within an occluded or non-occluded state, and
the implications for the transport of ions that this explains. In
addition to fundamentally linking “micro” scale processes and
biochemical control with “macro” scale transport of NTBI, we
elaborate the wider field of iron homeostasis and the uptake
of iron (not just NTBI) by cells by drawing conclusions about
how tPMET is used differentially in different circumstances, and
how this links to iron uptake. Transferrin-bound iron uptake is
the predominate method of iron uptake within the body when
in a healthy state. NTBI may exist up to 1µg/ml in a healthy
individual, although it is commonly undetectable, therefore
although some NTBI uptake may occur this is very small in
concern to overall iron levels. Therefore, in a healthy individual,
it can be said that NTBI uptake occurs at a consequential
level in two instances: at the lung epithelium where exposure
to the atmosphere yields a higher exposure to iron, and at
the gut epithelium (predominantly duodenum) where NTBI
uptake is the main source of dietary adsorption of iron. Despite
being used in certain instances in a healthy state, NTBI uptake
systems seem to be present throughout the body. This leads to
the explanation that NTBI uptake systems, that fundamentally
employ tPMET to achieve this, are a safeguard against situations
of iron overload and in disease states which may occur. We
have brought together unlinked data that suggests tPMET not
only plays a fundamental role in NTBI uptake in a state of
disease where iron overload is present, but also that they may
play a role when mitochondrial dysfunction occurs or where
metabolic stress leads to an imbalance of NAD(P)H/NAD(P)+
levels resulting in increased NAD(P)H levels. This is where
the cell uses tPMET to regenerate NAD(P)+ from NAD(P)H.
This work should be of interest to the wider community of
biology, because the work to date suggests a general mechanism
of control that should be able to be applied to all cellular redox
driven membrane transport systems. Similarly it should be of
interest to the chemical community, which will in turn highlight
the importance of how chemical systems modulate transport at
molecular scale in the biological systems.
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